Guizhou Xinbang Pharmaceutical Co Ltd (SHE:002390) — Market Cap & Net Worth
Market Cap & Net Worth: Guizhou Xinbang Pharmaceutical Co Ltd (002390)
Guizhou Xinbang Pharmaceutical Co Ltd (SHE:002390) has a market capitalization of $856.18 Million (CN¥5.85 Billion) as of October 10, 2026. Listed on the SHE stock exchange, this China-based company holds position #9574 globally and #2445 in its home market, demonstrating a 1.69% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guizhou Xinbang Pharmaceutical Co Ltd's stock price CN¥3.01 by its total outstanding shares 1943851868 (1.94 Billion).
Guizhou Xinbang Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Guizhou Xinbang Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $3.85 Billion to $856.18 Million (-11.84% CAGR). Check Guizhou Xinbang Pharmaceutical Co Ltd (002390) share price today for real-time trading data and today's change.
Guizhou Xinbang Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guizhou Xinbang Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see 002390 cash flow metrics for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.21x
Guizhou Xinbang Pharmaceutical Co Ltd's market cap is 0.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
12.77x
Guizhou Xinbang Pharmaceutical Co Ltd's market cap is 12.77 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.85 Billion | $4.18 Billion | $174.38 Million | 0.92x | 22.05x |
| 2016 | $2.66 Billion | $5.16 Billion | $246.01 Million | 0.52x | 10.81x |
| 2017 | $2.28 Billion | $6.00 Billion | $319.38 Million | 0.38x | 7.14x |
| 2018 | $1.11 Billion | $6.58 Billion | -$1.30 Billion | 0.17x | N/A |
| 2019 | $1.42 Billion | $6.66 Billion | $236.30 Million | 0.21x | 6.02x |
| 2020 | $2.30 Billion | $5.85 Billion | $173.52 Million | 0.39x | 13.24x |
| 2021 | $2.01 Billion | $6.47 Billion | $272.87 Million | 0.31x | 7.37x |
| 2022 | $1.29 Billion | $6.35 Billion | $224.37 Million | 0.20x | 5.75x |
| 2023 | $1.23 Billion | $6.46 Billion | $287.23 Million | 0.19x | 4.29x |
| 2024 | $1.29 Billion | $6.03 Billion | $101.38 Million | 0.21x | 12.77x |
Competitor Companies of 002390 by Market Capitalization
Companies near Guizhou Xinbang Pharmaceutical Co Ltd in the global market cap rankings as of October 10, 2026. See Guizhou Xinbang Pharmaceutical Co Ltd (002390) net asset quality to understand what proportion of total assets are financed by equity.
Key companies related to Guizhou Xinbang Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #524 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #585 globally with a market cap of $46.39 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #628 globally with a market cap of $43.73 Billion USD ( CN¥298.86 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #630 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #524 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #585 | GALDERMA GROUP AG | NYSE:GALDY | $46.39 Billion | $39.79 |
| #628 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.73 Billion | CN¥46.85 |
| #630 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.30 |
Guizhou Xinbang Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Guizhou Xinbang Pharmaceutical Co Ltd's market cap moved from $3.85 Billion to $ 856.18 Million, with a yearly change of -11.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥856.18 Million | -6.52% |
| 2025 | CN¥915.92 Million | -29.23% |
| 2024 | CN¥1.29 Billion | +4.93% |
| 2023 | CN¥1.23 Billion | -4.32% |
| 2022 | CN¥1.29 Billion | -35.88% |
| 2021 | CN¥2.01 Billion | -12.50% |
| 2020 | CN¥2.30 Billion | +61.52% |
| 2019 | CN¥1.42 Billion | +28.36% |
| 2018 | CN¥1.11 Billion | -51.39% |
| 2017 | CN¥2.28 Billion | -14.27% |
| 2016 | CN¥2.66 Billion | -30.85% |
| 2015 | CN¥3.85 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 10th, 2026 the market cap of Guizhou Xinbang Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $856.18 Million USD |
| MoneyControl | $856.18 Million USD |
| MarketWatch | $856.18 Million USD |
| marketcap.company | $856.18 Million USD |
| Reuters | $856.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guizhou Xinbang Pharmaceutical Co Ltd
Guizhou Xinbang Pharmaceutical Co., Ltd. manufactures and sells traditional Chinese medicine and other pharmaceutical products in China and internationally. The company cardiovascular and cerebrovascular, digestive system, endocrine, tumors and immunomodulatory drugs, blood system drugs, rheumatism and rheumatoid arthritis, urinary system, antipyretic and analgesic, cold medicine, gynecological m… Read more